Skip to content
Visit the website
Organization profile

EazeBio

Rapid hormone, metabolic and inflammation tests read by a phone at home or a dedicated reader in clinic, with trend tracking over time

Rapid biomarker tests read by a phone or a clinic reader, and the software that tracks them over time.

FDA device listings
7 active · Class I
Two assay formats
Lateral flow at home · fluorescent immunoassay in clinic
Peer-reviewed
Two 2026 Journal of Fluorescence papers
Co-development
Cortisol biosensor with UC Santa Cruz
Reviewed

Overview

A Livermore biosensing company with seven active FDA device listings and two 2026 papers, opening to clinics first and to individuals through early access.

EazeBio Inc. is a Livermore, California company that builds rapid biomarker tests and the software that reads them over time. The same assay chemistry runs two ways: a lateral-flow cassette read by a smartphone camera for wellness screening at home, and a fluorescent immunoassay on a dedicated reader for clinics and laboratories. The professional line carries seven active FDA device listings, its assay work is published in the Journal of Fluorescence, and it is co-developing a cortisol biosensor with UC Santa Cruz.

At a glance

Which assay format fits the setting, and how far along each line is.

Samples and timing
Fingerstick, saliva or urine · about 15 minutes
Access today
Clinical overview for professionals · early-access list for individualsClinical overview

Pricing

Services

Clinical and laboratory

  • Clinical and laboratory panels

  • Pilots, partnerships and research collaboration

Consumer wellness screening

  • Eaze Panel wellness panels

  • Single-analyte test kits

Food and water screening

  • Clean Plate

  • Safe Sip

Offerings

  • Clinical and laboratory panels
    Contact for pricing

    For professionals

    Fluorescent immunoassays on a dedicated reader for clinics and laboratories, compatible with LDT-style workflows, scoped through a clinical overview with the EazeBio team

    Panel scope, reader, sample types, throughput, output format and the regulatory basis for your setting are agreed in the overview.

    Request a clinical overviewLink verified
  • Pilots, partnerships and research collaboration
    Contact for pricing

    For professionals

    Clinical pilots, platform partnerships, preventive programs and research collaboration, scoped to the markers and care pathway a partner runs

    Contact the EazeBio teamLink verified
  • Clean Plate and Safe Sip panels
    Price not published

    For consumersWaitlist

    Clean Plate screens food for Staph toxin SEB, Salmonella, E. coli O157, Campylobacter and Norovirus; Safe Sip screens water for E. coli, Giardia, Cryptosporidium and V. cholerae, both in 15 minutes

    Both run on the EazeBio smartphone reader, from a food rinsate, surface swab or filtered water concentrate.

Clinics and laboratories: terms are scoped in a clinical overview covering panel scope, reader, workflow fit and the applicable regulatory basis.

Individuals: the Eaze Panel wellness panels, single-analyte kits and the Clean Plate and Safe Sip food and water panels open through an early-access list, which EazeBio says carries early-access pricing.

Prices checked 23 Sep 2026

Availability

Diagnostics

At home

  • EazeBio

    Seven symptom-led at-home panels, among them Always Tired (ferritin, B12, vitamin D, TSH, HbA1c) and Stressed & Inflamed (cortisol, hs-CRP, GDF-15), plus a build-your-own option across 21 biomarkers; launching through a waitlist, price not yet published

Diagnostic programs

  • EazeBio

    Seven one-marker kits: Prolactin, LH, FSH, AMH and Estradiol (E2) in FIA format, plus an Ovulation LH kit and an FSH (Menopause) kit; waitlist, price not yet published

Leadership and science team

The people who sign EazeBio's published assay work also run the company.

  • Reem Mahrat

    Founder and Chief Executive Officer

    First author on the 2026 Tau441 paper and corresponding author on the 2026 cortisol paper.

  • Ying Chen, PhD, MBA

    Co-founder and Chief Scientific Officer

    Co-author on both 2026 Journal of Fluorescence papers.

  • Sulatha Dwarakanath, PhD

    Chief Strategy Officer

  • Bill Howelle, MD, PhD

    Chief Medical Officer

  • Kevin Seltzer, JD, CPA

    Chief Financial Officer

  • Isam Alyousfir

    Chief Information Officer

  • Aditi Malu, PhD

    Vice President of R&D

  • Binh Lu

    Head of Manufacturing

  • John Bruno, PhD

    Advisor

    Co-author on both 2026 papers and first author on the cortisol assay.

Evidence and limitations

  • How it works

    EazeBio treats a test result as one input to a personal baseline. Samples from a fingerstick, saliva or urine run on the same chemistry at home or in clinic, and the digital layer normalizes the results and reports directional change over weeks and months rather than a single threshold crossing. The company says the layer is built to support clinical reasoning, not replace it.

  • Distinguishing details

    • Checkable registrations. Seven active FDA device listings across five markers, verifiable in the FDA's own database.
    • Published assay work. Two 2026 Journal of Fluorescence papers on cortisol and Tau441 assays, authored by its own team.
    • One chemistry, two settings. The phone-read cassette and the clinic reader share the same interpretive framework.
    • University co-development. An instrument-free cortisol biosensor with UC Santa Cruz, reported independently by SelectScience.
  • What to consider

    • For clinics: bring the markers your pathway already orders, and ask about the reader, accepted sample types, throughput and output format.
    • For individuals: the consumer panels open through early access; registering names the markers and setting you care about.
    • Reading results: EazeBio positions its consumer kits as wellness screening tools and asks that results be reviewed with a healthcare provider.

Frequently asked questions

Evidence and how to read it

The seven FDA device listings were confirmed in the FDA's device registration and listing database on 23 September 2026, and all seven product codes (CGJ, CEP, CFT, CFP, CHP, NGE, NGA) sit in class I with a 510(k)-exempt submission type. A device listing is the registration record a manufacturer files for a product in its class.

Both 2026 papers carry EazeBio's chief executive, chief scientific officer and an advisor as authors, so they are the company's own published work. The Tau441 paper describes itself as preliminary development, and its performance figures describe serum in a laboratory setting.

Published work

Transparency and sources

Trust

Registration

  • US Food and Drug Administration · device registration and listing

    Seven active device listings under registrant EAZEBIO (FEI 3047746876) for FSH, LH, prolactin, insulin and estradiol fluorescent immunoassays, all in device class I with a 510(k)-exempt submission type. A listing is the registration record a manufacturer files for a product in its class.

    FDA device registration and listing, FEI 3047746876

Directory listings are for informational purposes only. Inclusion does not constitute endorsement. Verify credentials and qualifications independently.

Keep exploring

Your Longevity Blueprint

Build your starting plan.

A few short questions, about two minutes. The Blueprint recommends where to start and explains why.

Build my Blueprint